A 12-Week, Randomized, Double-Blind, Placebo-Controlled Phase 2a Study with Factorial Design to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of TERN-501 Alone and in Combination with TERN-101 in Patients with NASH